Xenon Pharmaceuticals Inc. (XENE)
XENE Stock Price Chart
Explore Xenon Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze XENE price movements and trends.
XENE Company Profile
Discover essential business fundamentals and corporate details for Xenon Pharmaceuticals Inc. (XENE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Nov 2014
Employees
316.00
Website
https://www.xenon-pharma.comCEO
Ian C. Mortimer CPA,
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Financial Timeline
Browse a chronological timeline of Xenon Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.16.
Earnings released on 11 Aug 2025
EPS came in at -$1.07 falling short of the estimated -$1.03 by -3.88%.
Earnings released on 12 May 2025
EPS came in at -$0.83 surpassing the estimated -$0.94 by +11.70%, while revenue for the quarter reached $7.50M , beating expectations by +293.44%.
Earnings released on 27 Feb 2025
EPS came in at -$0.84 surpassing the estimated -$0.89 by +5.62%.
Earnings released on 12 Nov 2024
EPS came in at -$0.81 surpassing the estimated -$0.82 by +0.69%.
Earnings released on 8 Aug 2024
EPS came in at -$0.75 falling short of the estimated -$0.72 by -4.17%.
Earnings released on 9 May 2024
EPS came in at -$0.62 surpassing the estimated -$0.69 by +10.14%.
Earnings released on 29 Feb 2024
EPS came in at -$0.64 surpassing the estimated -$0.76 by +15.79%, while revenue for the quarter reached $5.38M , beating expectations by +184.66%.
Earnings released on 8 Nov 2023
EPS came in at -$0.73 surpassing the estimated -$0.75 by +2.67%.
Earnings released on 9 Aug 2023
EPS came in at -$0.72 falling short of the estimated -$0.69 by -4.35%.
Earnings released on 9 May 2023
EPS came in at -$0.63 falling short of the estimated -$0.62 by -1.61%.
Earnings released on 1 Mar 2023
EPS came in at -$0.57 surpassing the estimated -$0.58 by +1.72%, while revenue for the quarter reached $8.77K , missing expectations by -99.70%.
Earnings released on 8 Nov 2022
EPS came in at -$0.57 falling short of the estimated -$0.52 by -9.62%, while revenue for the quarter reached $132.00K , missing expectations by -96.82%.
Earnings released on 9 Aug 2022
EPS came in at -$0.55 falling short of the estimated -$0.49 by -12.24%, while revenue for the quarter reached $536.00K , missing expectations by -87.17%.
Earnings released on 10 May 2022
EPS came in at -$0.35 surpassing the estimated -$0.38 by +7.89%, while revenue for the quarter reached $8.77M , beating expectations by +13.29%.
Earnings released on 1 Mar 2022
EPS came in at -$0.57 falling short of the estimated -$0.47 by -21.28%, while revenue for the quarter reached $3.74M , missing expectations by -34.27%.
Earnings released on 10 Nov 2021
EPS came in at -$0.36 surpassing the estimated -$0.44 by +18.18%, while revenue for the quarter reached $8.12M , missing expectations by -15.38%.
Earnings released on 11 Aug 2021
EPS came in at -$0.51 falling short of the estimated -$0.49 by -4.08%, while revenue for the quarter reached $2.22M , meeting expectations.
Earnings released on 11 May 2021
EPS came in at -$0.42 surpassing the estimated -$0.45 by +6.67%, while revenue for the quarter reached $4.36M , missing expectations by -2.27%.
Earnings released on 1 Mar 2021
EPS came in at -$0.34 surpassing the estimated -$0.40 by +15.00%, while revenue for the quarter reached $5.15M .
Earnings released on 5 Nov 2020
EPS came in at -$0.25 falling short of the estimated -$0.15 by -66.67%, while revenue for the quarter reached $6.55M , beating expectations by +21.21%.
XENE Stock Performance
Access detailed XENE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.